SEC Filing Analysis: ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Routine compensation event; insider sold shares strictly for tax withholding while receiving substantial new equity grants.
• Market Impact: Neutral/None. The transaction volume is negligible relative to the company's $44B valuation.

Company Information

Field	Value
Company	ALNYLAM PHARMACEUTICALS, INC.
Ticker Symbol	ALNY
CIK	0001178670
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Tanguler Tolga
CIK	0001849458
Title/Position	EVP, Chief Commercial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-03-02
Transaction Code	S (Sale), A (Grant)
Security Type	Common Stock & Options
Shares Sold	1,598 (Aggregated)
Avg Price Per Share	~$328.00 (Weighted Avg)
Total Sale Value	~$524,144
Shares Owned After	36,606
Ownership Type	Direct

Note: The insider also received a grant of 4,769 RSUs and 10,480 Stock Options on the same day.

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value (Sales)	~$0.52 Million
% of Market Cap	~0.001%
Shares Transacted	1,598
% of Shares Outstanding	~0.001%
Post-Transaction Ownership	36,606 shares (0.02% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market cap of $44.15 billion, a $500k transaction is statistically insignificant noise.
• Ownership Concentration: The insider holds a modest position typical for an EVP level, representing a fraction of a percent of the company.
• Dilution Impact: The new grants (4,769 RSUs + 10,480 Options) represent ~0.01% potential dilution, which is standard for executive compensation.
• Transaction Significance: The sales are explicitly flagged in Footnote F2 as "mandatory sell-to-cover" for taxes. This is administrative, not sentiment-driven.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sales are mechanical and tax-related. The net result of the filing is actually an increase in the insider's potential equity stake via the new option and RSU grants.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral. Investors typically disregard sell-to-cover transactions as they do not reflect the insider's view on valuation.

Additional Context

Transaction Notes

• Tax Withholding: Footnote F2 confirms shares were sold "pursuant to a mandatory sell-to-cover provision" to satisfy tax obligations.
• New Incentives: The insider received 10,480 stock options exercisable at $325.07 (expiring 2036) and 4,769 RSUs, reinforcing long-term retention.
• Price Action: Sales occurred in a tight range between $323 and $332, consistent with market pricing on the transaction date.